Search

Displaying results 5911 - 5920 of 9694 in total
  1. Drug

    Vibegron

    go.drugbank.com/drugs/DB14895
    ApprovedInvestigational

    Vibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. … [L28305] Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency,

  2. Drug

    Inclisiran

    go.drugbank.com/drugs/DB14901
    ApprovedInvestigational

    Inclisiran is a long-acting, synthetic small interfering RNA (siRNA) directed against proprotein convertase subtilisin-kexin type 9 (PCSK9), which is a serine protease that regulates plasma low-density … A225953,A225958] Lowering circulating plasma LDL-C levels offers an additional benefit of reducing the risk of cardiovascular disease (CVD) and improving cardiovascular outcomes, as hypercholesterolemia is a

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Emactuzumab

    go.drugbank.com/drugs/DB14905
    Investigational

    Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).

  4. Drug

    Bevacizumab zirconium Zr-89

    go.drugbank.com/drugs/DB14907
    Investigational

    Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [A260192] As a result, the main clinical manifestation of myasthenia gravis is easily fatigable or persistent muscle weakness. … Rozanolixizumab is a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P) targeting the immunoglobulin G (IgG).

  6. Drug

    Iboctadekin

    go.drugbank.com/drugs/DB14920
    Investigational

    Iboctadekin is under investigation in clinical trial NCT00500058 (A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18).

  7. Drug

    Ritlecitinib

    go.drugbank.com/drugs/DB14924
    ApprovedInvestigational

    [A260122,A260127] Ritlecitinib binds covalently to Cys-909 of JAK3, a site where other JAK isoforms have a serine residue. … [A260122,A260127] Other kinases have a cysteine at a position equivalent to Cys-909 in JAK3, and several of them belong to the TEC kinase family.

  8. Drug

    Firtecan pegol

    go.drugbank.com/drugs/DB14953
    Investigational

    Firtecan pegol is under investigation in clinical trial NCT01036113 (A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer).

  9. Drug

    MK-3577

    go.drugbank.com/drugs/DB14957
    Investigational

    MK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)).

  10. Drug

    CTT-1057

    go.drugbank.com/drugs/DB14965
    Investigational

    CTT-1057 is under investigation in clinical trial NCT03427476 (CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma).